FAQ on Oragenics Inc.'s $16.5 Million Preferred Stock Offering for Intranasal Concussion Therapy Development
Summary
Oragenics Inc. has successfully raised $16.5 million through a public offering of Series H Convertible Preferred Stock and Warrants to advance its intranasal therapy for concussions, with proceeds also allocated for debt repayment and R&D.
What is the purpose of Oragenics Inc.’s recent stock offering?
The purpose of the stock offering was to raise approximately $16.5 million to fund the clinical development of ONP-002 for concussion, repay a $3 million bridge note, and support R&D and general operations.
How much did Oragenics Inc. raise in its recent public offering?
Oragenics Inc. raised approximately $16.5 million in gross proceeds from the sale of 660,000 units of Series H Convertible Preferred Stock and Warrants at $25.00 per unit.
What could the additional proceeds be if the Warrants are fully exercised?
If the Warrants are fully exercised, they could yield an additional $16.5 million for Oragenics Inc.
What is ONP-002?
ONP-002 is Oragenics Inc.’s intranasal therapeutic candidate for treating mild traumatic brain injury (mTBI), also known as concussion.
Who acted as the sole placement agent for Oragenics Inc.’s public offering?
Dawson James Securities acted as the sole placement agent for the public offering.
Where can I find more information about Oragenics Inc.?
More information about Oragenics Inc. can be found on the company’s website at www.Oragenics.com or in the company’s newsroom at https://ibn.fm/OGEN.
What are the other areas of focus for Oragenics Inc.?
Oragenics Inc. is also focused on fighting infectious diseases, including drug candidates for treating Niemann Pick Disease Type C (NPC), as well as developing proprietary powder formulation and an intranasal delivery device.
How can I view the full press release about Oragenics Inc.’s public offering?
The full press release can be viewed at https://ibn.fm/5Urvg.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 99452